Not all acute coronary syndrome patients get appropriate tx

Not all acute coronary syndrome patients get appropriate tx
Nearly one in five eligible patients hospitalized for acute coronary syndrome do not receive American College of Cardiology/American Heart Association class I guideline-recommended angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy, according to a study published online Feb. 25 in Circulation: Cardiovascular Quality and Outcomes.

(HealthDay)—Nearly one in five eligible patients hospitalized for acute coronary syndrome do not receive American College of Cardiology/American Heart Association (ACC/AHA) class I guideline-recommended angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy, according to a study published online Feb. 25 in Circulation: Cardiovascular Quality and Outcomes.

Kevin R. Bainey, M.D., from the University of Alberta in Edmonton, Canada, and colleagues examined the extent to which ACEI/ARB therapy is applied in patients with . Data were collected from 80,241 patients admitted with an acute coronary syndrome and discharged home from 311 U.S. hospitals participating in the Get With the Guidelines-Coronary Artery Disease Program (January 2005 to December 2009).

The researchers found that 81 percent of the 60,847 patients with an ACC/AHA class I indication (left ventricular dysfunction or medical history of heart failure, hypertension, diabetes mellitus, or ) received ACEI/ARB. The rate of treatment increased over the study period (76.7 to 84.6 percent; adjusted odds ratio [OR], 1.17; P < 0.001, per calendar year). There were independent associations between in-hospital coronary bypass grafting (adjusted OR, 0.55) and renal insufficiency (adjusted OR, 0.58) with lower usage.

"These findings highlight an unmet need in this population and provide an incentive for additional quality improvement efforts," the authors write.

The Get With the Guidelines-Coronary Artery Disease Program is supported in part by Merck/Schering-Plough and Pfizer. Several authors disclosed financial ties to the medical device and pharmaceutical industries.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Clinical outcomes similar for elderly with PCI, CABG

Aug 27, 2013

(HealthDay)—For older patients with unprotected left main coronary artery disease, clinical outcomes are similar with percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), ...

Recommended for you

Post-PCI bleeding rates vary widely across hospitals

3 hours ago

(HealthDay)—Patient case-mix and procedural factors may contribute to wide variation in the hospital rates of bleeding after percutaneous coronary intervention (PCI), according to research published online ...

Most seniors eligible for statin Rx under new guidelines

Nov 25, 2014

(HealthDay)—Most older Americans qualify for treatment with statins under new guidelines for the treatment of blood cholesterol released late last year by the American College of Cardiology and the American ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.